Merck's Keytruda Sales Smash Forecasts Reaching $10 Billion
A key product from Merck has significantly outperformed market forecasts.
The company's 'Keytruda' drug, used to treat various types of cancer, has seen its sales jump by a substantial margin.
According to available data, the pharmaceutical giant's revenues from Keytruda have surpassed analysts' expectations, with sales exceeding $10 billion in 2023.